Matrix to Pursue Strategic Alternatives Including Potential Divestiture of Docpharma

Secunderabad, India-Feb. 28, 2008-Matrix Laboratories Limited, a subsidiary of Mylan Inc. (NYSE: MYL), today announced that its Board of Directors has authorized its management to pursue strategic alternatives up to and including the divestiture of its Docpharma subsidiary, a leading marketer and distributor of generic pharmaceuticals in Belgium, the Netherlands and Luxemburg ("Benelux").

Shortly following Matrix's acquisition of Docpharma, Matrix underwent significant activity including the acquisition of a 71.5% controlling interest by Mylan, a U.S.-based generics pharmaceutical company. Since then, Matrix has realigned its strategic focus with Mylan to yield greater value for shareholders. In light of Mylan's acquisition of Merck Generics, Matrix will further refocus its business to reflect the importance of strategic arrangements with Mylan in support of its enlarged global platform.

Robert J. Coury, Matrix's Non-Executive Chairman stated, "After careful review and upon recommendation from its senior management team, Matrix has decided to explore strategic alternatives for Docpharma including a potential sale. We believe our determination represents better growth in shareholder value for our shareholders. As it has continued to realign itself to predominantly serve Mylan's global generics business, Matrix will also continue to focus on its core API business and finished dosage form development as well as on the continued growth of its antiretroviral business. Docpharma offers a strong platform for the marketing and distribution of generic pharmaceuticals in the Benelux countries. We believe that Docpharma will be better situated in an organization that is compatible with its core competencies."

Strategic alternatives for Docpharma, up to and including divestiture, remain subject to approval by Matrix shareholders. Matrix will provide further detail once it has reached any definitive agreement.

Matrix Laboratories Limited, a subsidiary of Mylan Inc., USA, is a public limited company listed on BSE and NSE, and is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms. Matrix is one of the fastest growing API manufacturers in India and focuses on regulated markets such as U.S. and EU. The company has a wide range of products in CNS, anti-bacterial, anti-AIDS, anti-asthmatic, cardiovascular, gastrointestinal, anti-fungal, pain management and life style related therapeutic segments. All API and FDF manufacturing facilities of the Matrix are approved by the US FDA. For more information about Matrix please visit www.matrixlabsindia.com